Astral Systems
Astral Systems uses multi-state fusion technology to produce medical isotopes and neutrons for healthcare, industrial and scientific applications.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Tsuga, Astral Systems, VARM — AI observability, medical isotopes and retrofit become infrastructure — Daily News June 23, 2026
Listen to the episodeAbout Astral Systems
Astral Systems is a Bristol-based deep-tech company founded in 2021. The company develops modular reactors based on multi-state fusion to produce critical medical isotopes and make a fragile, concentrated supply chain more resilient. Its €26M Series A will support reactor scaling and the commercial launch of medical isotopes by early 2027.
The Story
The company was founded in 2021 by Talmon Firestone and Dr Tom Wallace-Smith.
How Astral Systems works
Business Model
B2B production and supply of medical isotopes and neutron-source research contracts.
Revenue Model
Revenue from research contracts and future supply of medical isotopes.
Products & Services
Key Products
- Multi-state fusion reactors
- Medical isotope production platform
Core Use Cases
- Medical isotope production
- Nuclear medicine
- Research neutron sources
- Industrial irradiation
Market & Clients
Key Customers
Healthcare markets, nuclear research, industry and nuclear medicine suppliers; specific customers are not fully disclosed.
Geographic Presence
How Astral Systems competes
Competitive Advantages
- Compact modular reactors
- Near-market application in medical isotopes
- Existing revenue from research contracts
How Astral Systems grows
Growth Strategy
Bring medical isotopes to market by 2027 and scale production capacity.
Distribution Model
B2B sales and partnerships with healthcare, industrial and research organisations.
Moat (Defensibility)
Proprietary multi-state fusion technology, nuclear expertise and specialised production infrastructure.
Regulatory Context
Subject to nuclear, healthcare and safety regulation for isotope production and distribution.
Key Risks
- Technical risk
- Nuclear and healthcare regulatory risk
- Industrialisation timelines
- Capital intensity
Strategic Insights
- Deep tech can reach the market through high-value vertical applications.
- Healthcare can be a concrete commercial market for technologies born in energy.
- Medical supply-chain resilience is an industrial issue, not only a healthcare issue.
Funding & Investors
Total Funding
Funding Rounds
- 2026 - Series A: €26M / £23M
Lead: Mercia Ventures
Key Investors
Founding Team
Founders
Key Executives
- Talmon Firestone - Co-founder & CEO
Key Metrics
Lessons from Astral Systems
- Medical applications can give complex deep-tech platforms a commercial path.
- Research contracts can help finance and validate the technology before full industrialisation.
- Choosing the right first market is critical to make hard technology investable.
Similar Startups
BioOrbit
BioOrbit is a British startup that raised £9.8M seed in 2026 to manufacture cancer drugs in space. It develops an autonomous unit called BOX that uses microgravity to crystallize anti-cancer antibodies in purer form, potentially enabling subcutaneous administration formulations.
Read AnalysisCMR Surgical
CMR Surgical is a European healthtech platform with a public unicorn valuation.
Read AnalysisiFAST Diagnostics
UK biotech developing rapid antimicrobial susceptibility testing with results in under three hours.
Read Analysis